Item 8.01 Other Events
On January 2, 2020, DURECT Corporation issued a press release announcing the
results from its Phase 2a clinical trial of DUR-928 in patients with mild to
moderate plaque psoriasis. Twenty-two patients completed the study, applying
DUR-928 topically to the plaque on one arm and the vehicle (placebo) to a
similar plaque on the other arm daily for 28 days. DUR-928 did not demonstrate a
benefit over vehicle (placebo) based on Investigator's Global Assessment (IGA),
which was the scoring system for the primary analysis, or in any of the
secondary analyses. Daily topical application of DUR-928 was well tolerated with
no meaningful differences in adverse events between the treatment and vehicle
(placebo) groups. There were no AEs attributed to the study drug. A copy of the
press release is attached as Exhibit 99.1 to this Form 8-K and incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release of DURECT Corporation dated January 2, 2020
3
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses